Ketamine for OCD: Glutamatergic Modulation of Obsessive-Compulsive Circuits

Ketamine for OCD is an experimental treatment approach with early but limited clinical evidence. Small studies suggest that some adults with severe, treatment-resistant obsessive-compulsive disorder may have a rapid reduction in obsessive symptoms after ketamine, but the benefit can be short-lived and the best dose, schedule, and long-term strategy remain unclear. Ketamine is not a standard first-line OCD treatment. Evidence-based care still centers on exposure and response prevention therapy and serotonin reuptake inhibitor medicines, as described by the National Institute of Mental Health.

OCD involves recurring obsessions, compulsions, or both. Researchers are studying ketamine because it blocks the N-methyl-D-aspartate receptor, commonly called the NMDA receptor, and may temporarily alter glutamate signaling in brain circuits involved in repetitive thoughts and behaviors.

Why glutamate is being studied in OCD

The leading neurobiological model of OCD focuses on cortico-striato-thalamo-cortical circuits. These connected brain pathways include the orbitofrontal cortex, anterior cingulate cortex, striatum, and thalamus. Imaging and neurochemical research has linked OCD with differences in activity and glutamate-related signaling in parts of these circuits, although these findings do not establish one single cause of OCD.

Glutamate is the brain's main excitatory neurotransmitter. NMDA and AMPA receptors help regulate how glutamate signals between neurons. Ketamine's effects on NMDA receptors may trigger downstream changes in synaptic signaling and plasticity, which is one reason researchers are testing it for conditions beyond depression. Read more about the proposed biology in our guide to neuroplasticity and ketamine.

Preclinical work also supports continued study. For example, animal models of compulsive behavior have found that altering glutamate pathways can change repetitive behaviors. These models help generate hypotheses, but they cannot show that a treatment will work safely or durably in people with OCD.

What clinical studies of ketamine for OCD show

The most cited controlled study is a 2013 randomized, double-blind, placebo-controlled crossover trial by Rodriguez and colleagues. Fifteen adults received a single intravenous ketamine infusion of 0.5 mg/kg over 40 minutes and saline placebo in separate sessions. At one week, the ketamine condition showed a greater average reduction in Yale-Brown Obsessive Compulsive Scale scores than placebo. The study is available through PubMed.

Small case series, open-label studies, and later work involving repeated or intranasal administration have reported possible short-term symptom improvement. Their designs and sample sizes limit what readers can conclude. Open-label studies do not include a blinded placebo comparison, and small trials can overestimate benefit or miss less common harms.

A systematic-review search in PubMed shows why the topic remains unsettled: the available literature is small and uses different routes, schedules, participant groups, and outcome measures. Current evidence supports further research, not a settled protocol for routine OCD care.

Could ketamine help with exposure and response prevention?

Exposure and response prevention, often called ERP, is a form of cognitive-behavioral therapy designed to reduce compulsions and change a person's response to intrusive thoughts. It is a core evidence-based treatment for OCD. Researchers have proposed that ketamine's short-term effects on learning and synaptic plasticity could make ERP easier to engage with during a limited treatment window. That idea is plausible but not established as standard care.

For a person considering treatment, the practical question is not simply whether ketamine can produce a rapid change. It is whether any improvement can support sustained work with an OCD specialist, an ERP plan, and appropriate follow-up. Our article on ketamine integration therapy explains why follow-up support is often part of the broader treatment conversation.

Safety and treatment considerations

Ketamine can cause dissociation, changes in blood pressure and heart rate, nausea, dizziness, sedation, and perceptual changes during or shortly after treatment. A clinician should review medical history, current medicines, substance use history, psychiatric symptoms, and monitoring needs before discussing whether ketamine is appropriate. Medication interactions deserve specific review, including with medicines that affect sedation or blood pressure. See our overview of ketamine drug interactions and our guide to cardiovascular monitoring.

People should also ask whether a clinician is treating OCD directly, coordinating with an ERP therapist, and measuring symptoms with a validated tool such as the Yale-Brown Obsessive Compulsive Scale. A rapid change in symptoms does not by itself establish durable recovery or replace a complete OCD treatment plan.